Dalton Pharma Services, a privately owned Canadian pharmaceutical services provider to leading pharmaceutical companies, today announced successful completion of its recent Health Canada audit. The Company has received a 'Compliant' rating following the regulatory agency's inspection of Dalton's GMP manufacturing facility.
The Establishment License issued by Health Canada will enable Dalton Pharma Services to continue to manufacture, test and ship sterile commercial products for its existing clients. In addition, Dalton's solid dose manufacturing suites were also inspected and found to be compliant for formulation, granulation and encapsulation of drug products.
In separate audits by Qualified Persons, Dalton Pharma Services was also found to be compliant with GMP API manufacturing, sterile filling and testing standards for pharmaceutical products in the European Union.
"These successful inspections will allow us to continue to execute on our vision to accelerate drug development for our clients' pharmaceutical products globally. Dalton's ability to carry out commercial manufacture of sterile, solid dose pharmaceuticals and API provides integrated drug development and manufacturing solutions. Dalton's reputation for its ability to complete complex drug manufacturing projects in GMP compliant facilities enhances our clients' success in bringing the medicines of the future to the market," said Peter Pekos, President and CEO.